In the ongoing human effort to outpace the slow erosion of cardiovascular disease, a large real-world study has offered meaningful evidence that tirzepatide — a dual-action diabetes medication — may do more than manage blood sugar. Analyzing insurance records from over 52,000 patients across the United States, researchers found that those with type 2 diabetes and existing heart disease who took tirzepatide experienced roughly a third fewer major cardiovascular events than those on sitagliptin, a drug known to be heart-neutral. The finding, published in The BMJ, does not close the conversation